Vortimal Contraindications

Hypersensitivity to the active substance or to any of the excipients used in Vortimal.
Coadministration with CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide or quinidine since increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes (see Interactions).
Coadministration with rifampicin, carbamazepine and phenobarbital since these medicinal products are likely to decrease plasma voriconazole concentrations significantly (see Interactions).
Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg once daily or higher is contraindicated because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations (see Interactions, for lower doses see Precautions).
Coadministration with high-dose ritonavir (400 mg and above twice daily) because ritonavir significantly decreases plasma voriconazole concentrations in healthy subjects at this dose (see Interactions, for lower doses see Precautions).
Coadministration with ergot alkaloids (ergotamine, dihydroergotamine), which are CYP3A4 substrates, since increased plasma concentrations of these medicinal products can lead to ergotism (see Interactions).
Coadministration with sirolimus since voriconazole is likely to increase plasma concentrations of sirolimus significantly (see Interactions).
Coadministration with St John's Wort (see Interactions).